09.00 a.m. |
Welcome
Isabelle Schmitt-Opitz / Matthias Guckenberger, University Hospital Zurich |
|
Session 1: Perioperative immunotherapy – Isabelle Schmitt-Opitz & Christian Gutschow |
09.05 a.m. |
Immunotherapy for everyone? Mastering the challenges of perioperative immunotherapy for lung cancer
Brendon Stiles, Montefiore Health System, Albert Einstein College of Medicine, New York |
09.30 a.m. |
ESOPEC and clinical trials on immunotherapy for colorectal cancer
Christiane Bruns, University Hospital Cologne |
09.55 a.m. |
Side effects of IT in the perioperative area
Jordi Remon Masip, Gustave Roussy, Paris |
10.20 a.m. |
Coffee break |
|
Session 2: Oncology – Anja Lorch & Ralph Fritsch |
10.45 a.m. |
The microbiome to overcome resistance to cancer immunotherapies
Michael Scharl, University Hospital Zurich |
11.10 a.m. |
Renal cell cancer: Immuno-oncology 2024 and beyond
Manuela Schmidinger, Medical University of Vienna |
11.35 a.m. |
Targeting the immune desert – immunotherapy for pancreatic cancer
Jens Siveke, University Hospital Essen |
12.00 p.m. |
New immunotherapy approaches for melanoma
Reinhard Dummer, University Hospital Zurich |
12.25 p.m. |
Lunch |
1.10 p.m. |
Welcome Director of University Medicine Zurich
Beatrice Beck-Schimmer |
|
Session 3: Optimal combination of radiotherapy and immunotherapy – what’s new?
Panagiotis Balermpas & Matthias Guckenberger |
1.15 p.m. |
Keynote lecture: Radiotherapy-immunotherapy combinations, current and future perspectives
Silvia C. Formenti, Weill Cornell, New York |
1.40 p.m. |
Challenges on the way to personalized radio-immunotherapy combination treatments
Eric Deutsch, Gustave Roussy, Paris |
2.05 p.m. |
Clinical implementation of the combination of immuno-radiotherapy using the example of head and neck cancer: How can synergies between the treatment modalities be optimized?
Kevin Harrington, Royal Marsden, United Kingdom |
2.30 p.m. |
Lymphatic sparing improves the response to radiotherapy
Martin Pruschy, University Hospital Zurich |
2.55 p.m. |
Coffee break |
|
Session 4: Patrick Roth & Markus G. Manz |
3.30 p.m. |
Anti-angiogenic immunotherapy
Arjan Griffioen, Amsterdam UMC |
3.55 p.m. |
Overcoming exhaustion in cancer immunotherapy
Alfred Zippelius, University of Basel |
4.20 p.m. |
Neurological complications of cancer immunotherapy
Antoine Carpentier, Paris |
4.45 p.m. |
Conclusion
Panagiotis Balermpas / Markus G. Manz, University Hospital Zurich |